[go: up one dir, main page]

HK1109617A1 - Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same c - Google Patents

Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same c

Info

Publication number
HK1109617A1
HK1109617A1 HK08100120.5A HK08100120A HK1109617A1 HK 1109617 A1 HK1109617 A1 HK 1109617A1 HK 08100120 A HK08100120 A HK 08100120A HK 1109617 A1 HK1109617 A1 HK 1109617A1
Authority
HK
Hong Kong
Prior art keywords
hepatitis
treatments
inhibitors
compositions
same
Prior art date
Application number
HK08100120.5A
Other languages
English (en)
Inventor
Javier Gonzalez
Tanya Michelle Jewell
Hui Li
Angelica Linton
John Howard Tatlock
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Priority to HK10102850.3A priority Critical patent/HK1134676A1/xx
Publication of HK1109617A1 publication Critical patent/HK1109617A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK08100120.5A 2004-08-18 2008-01-07 Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same c HK1109617A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
HK10102850.3A HK1134676A1 (en) 2004-08-18 2008-01-07 Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same c

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60261804P 2004-08-18 2004-08-18
PCT/IB2005/002697 WO2006018725A1 (en) 2004-08-18 2005-08-05 Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same

Publications (1)

Publication Number Publication Date
HK1109617A1 true HK1109617A1 (en) 2008-06-13

Family

ID=35429645

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08100120.5A HK1109617A1 (en) 2004-08-18 2008-01-07 Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same c

Country Status (43)

Country Link
US (3) US7151105B2 (no)
EP (1) EP1781662B1 (no)
JP (1) JP4372195B2 (no)
KR (1) KR100851178B1 (no)
CN (2) CN101006092B (no)
AP (1) AP2313A (no)
AR (1) AR050699A1 (no)
AT (1) ATE506364T1 (no)
AU (1) AU2005273619B2 (no)
BR (1) BRPI0514425A (no)
CA (1) CA2577525C (no)
CR (2) CR8935A (no)
CY (1) CY1111480T1 (no)
DE (1) DE602005027580D1 (no)
DK (1) DK1781662T3 (no)
EA (1) EA012605B1 (no)
EC (1) ECSP077264A (no)
ES (1) ES2361845T3 (no)
GE (2) GEP20094751B (no)
GT (1) GT200500221A (no)
HK (1) HK1109617A1 (no)
HN (1) HN2005000449A (no)
HR (1) HRP20110458T1 (no)
IL (2) IL180933A (no)
MA (1) MA28803B1 (no)
MX (1) MX2007001527A (no)
MY (1) MY146123A (no)
NI (1) NI200700043A (no)
NL (1) NL1029755C2 (no)
NO (1) NO20071274L (no)
NZ (1) NZ552874A (no)
PE (1) PE20060677A1 (no)
PL (1) PL1781662T3 (no)
PT (1) PT1781662E (no)
RS (1) RS51794B (no)
SI (1) SI1781662T1 (no)
SV (1) SV2007002202A (no)
TN (1) TNSN07066A1 (no)
TW (1) TWI376379B (no)
UA (1) UA88909C2 (no)
UY (1) UY29068A1 (no)
WO (1) WO2006018725A1 (no)
ZA (1) ZA200700779B (no)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1781662T3 (pl) * 2004-08-18 2011-08-31 Pfizer Inhibitory zależnej od RNA polimerazy RNA wirusa zapalenia wątroby typu C, i kompozycje i terapie wykorzystujące je
CN102336758A (zh) * 2005-08-24 2012-02-01 辉瑞有限公司 作为hcv聚合酶抑制剂的化合物及组合物
ES2381410T3 (es) 2007-05-04 2012-05-28 Vertex Pharmceuticals Incorporated Terapia de combinación paa el tratamiento de infecciones por VHC
EP2008996A1 (en) * 2007-06-27 2008-12-31 Syngeta Participations AG Process for the production of pyrazoles
JP5820722B2 (ja) 2008-06-06 2015-11-24 スシネキス インク シクロスポリン類似体及びｈｃｖ感染の治療におけるその使用
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
AU2009281198B2 (en) 2008-08-11 2014-09-25 Glaxosmithkline Llc Novel adenine derivatives
MX2011001662A (es) 2008-08-11 2011-03-24 Glaxosmithkline Llc Derivados de purina para usarse en el tratamiento de enfermedades alergicas, inflamatorias e infecciosas.
UY32940A (es) 2009-10-27 2011-05-31 Bayer Cropscience Ag Amidas sustituidas con halogenoalquilo como insecticidas y acaricidas
CA2779244A1 (en) 2009-10-30 2011-05-05 Boehringer Ingelheim International Gmbh Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
EP2325173A1 (de) 2009-11-19 2011-05-25 Bayer CropScience AG Verfahren zum Herstellen von 5-Fluor-1-alkyl-3-fluoralkyl-1H-pyrazol-4-carbonsäurechloriden
KR20120116404A (ko) 2009-12-18 2012-10-22 베링거 인겔하임 인터내셔날 게엠베하 Ｈｃｖ 병용 요법
EP2534148A1 (en) 2010-02-10 2012-12-19 GlaxoSmithKline LLC Purine derivatives and their pharmaceutical uses
DK2534149T3 (da) 2010-02-10 2015-01-05 Glaxosmithkline Llc 6-amino-2-{ [ (1s)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8h-purin-8-on-maleat
ES2528646T3 (es) * 2010-05-20 2015-02-11 Bayer Intellectual Property Gmbh Procedimiento para la fabricación de 1-alquil-3-difluorometil-5-hidroxipirazoles
US8987307B2 (en) 2011-03-03 2015-03-24 Hoffmann-La Roche Inc. 3-amino-pyridines as GPBAR1 agonists
FR2972452B1 (fr) * 2011-03-09 2013-03-15 Rhodia Operations Procede de preparation du difluoroacetonitrile et de ses derives
US9145369B2 (en) 2012-05-14 2015-09-29 Bayer Cropscience Ag Process for preparing 1-alkyl-3-fluoroalkyl-1H-pyrazole-4-carboxylic acid chlorides
US9163027B2 (en) 2012-11-21 2015-10-20 Stategics, Inc. Substituted triazolo-pyrimidine compounds for modulating cell proliferation differentiation and survival
EP2945933B1 (en) 2013-01-17 2016-10-12 Bayer Cropscience AG Process for preparing 5-fluoro-1-methyl-3-difluoromethyl-1h-pyrazole-4-carbaldehyde
KR102191469B1 (ko) 2013-02-06 2020-12-16 바이엘 애니멀 헬스 게엠베하 해충 방제제로서의 할로겐-치환된 피라졸 유도체
AU2014375265B2 (en) 2014-01-03 2018-11-01 Elanco Animal Health Gmbh Novel pyrazolyl-heteroarylamides as pesticides
KR102319577B1 (ko) 2014-01-24 2021-10-29 바이엘 크롭사이언스 악티엔게젤샤프트 １-알킬-３-디플루오로메틸-５-플루오르-１ｈ-피라졸-４-카르브알데히드 및 １-알킬-３-디플루오로메틸-５-플루오르-１ｈ-피라졸-４-카르복실레이트의 제조 방법
RU2676684C2 (ru) 2014-02-20 2019-01-10 ГлаксоСмитКлайн Интеллекчуал Проперти (No.2) Лимитед ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНДУКТОРОВ ЧЕЛОВЕЧЕСКОГО ИНТЕРФЕРОНА
UA121548C2 (uk) 2014-06-03 2020-06-25 Ідорсія Фармасьютікалз Лтд Піразольні сполуки та їх застосування як блокаторів кальцієвих каналів t-типу
BE1023340B1 (fr) 2014-11-13 2017-02-08 Glaxosmithkline Biologicals S.A. Composes
WO2017093180A1 (de) 2015-12-01 2017-06-08 Bayer Cropscience Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
TWI704154B (zh) 2015-12-03 2020-09-11 英商葛蘭素史克智慧財產發展有限公司 新穎化合物
HRP20220936T1 (hr) 2016-04-07 2022-10-28 Glaxosmithkline Intellectual Property Development Limited Heterociklički amidi korisni kao modulatori proteina
CA3019628A1 (en) 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
RU2019107162A (ru) 2016-08-15 2020-09-15 Байер Кропсайенс Акциенгезельшафт Конденсированные бициклические гетероциклические производные в качестве средств для борьбы с вредителями
EP3301094A1 (en) * 2016-09-30 2018-04-04 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
IL267306B (en) 2016-12-16 2022-07-01 Idorsia Pharmaceuticals Ltd Pharmaceutical combination comprising a t-type calcium channel blocker
ES2971626T3 (es) 2017-02-06 2024-06-06 Idorsia Pharmaceuticals Ltd Un proceso novedoso para la síntesis de 1-aril-1-trifluorometilciclopropanos
AU2018344370C1 (en) 2017-10-04 2023-04-27 Bayer Aktiengesellschaft Derivatives of heterocyclic compounds as pest control agents
JP7291130B2 (ja) 2017-10-05 2023-06-14 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド インターフェロン遺伝子の刺激物質（ｓｔｉｎｇ）の調節物質
EP3692033A1 (en) 2017-10-05 2020-08-12 GlaxoSmithKline Intellectual Property Development Limited Modulators of stimulator of interferon genes (sting) useful in treating hiv
BR112020017624A2 (pt) 2018-03-12 2020-12-22 Bayer Aktiengesellschaft Derivados heterocíclicos bicíclicos condensados como agentes de controle de pragas
JP2021522182A (ja) 2018-04-20 2021-08-30 バイエル・アクチエンゲゼルシヤフト 殺有害生物剤としてのヘテロシクレン誘導体
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
WO2020232378A1 (en) 2019-05-16 2020-11-19 Silicon Swat, Inc. Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use
WO2020232375A1 (en) 2019-05-16 2020-11-19 Silicon Swat, Inc. Oxoacridinyl acetic acid derivatives and methods of use
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
JP2023506899A (ja) 2019-12-18 2023-02-20 シーティーエックスティー・ピーティーワイ・リミテッド 化合物
CN112194620B (zh) * 2020-12-04 2021-02-26 苏州开元民生科技股份有限公司 一种2-乙基-4-氰基吡啶的制备方法
CN113563167B (zh) * 2021-07-16 2023-09-08 南通华祥医药科技有限公司 一种2-甲基-1-四氢萘酮的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3786063A (en) 1971-05-24 1974-01-15 Universal Oil Prod Co Thiazolethiosulfonates
DE2155360C3 (de) * 1971-11-08 1980-04-03 Cassella Ag, 6000 Frankfurt Verfahren zur Herstellung von Acylbernsteinsäuredialkylestern
CA1144937A (en) 1977-12-22 1983-04-19 Dke J.E. Helgstrand Aromatic derivatives, pharmaceutical compositions and methods for combatting virus infections
US4326058A (en) 1979-02-05 1982-04-20 Sumitomo Chemical Company, Limited Organo-phosphoric esters and their production and use
US4489077A (en) 1983-03-23 1984-12-18 Warner-Lambert Company 3-Isoxa-zolyl-2H-1,2-benzothiazine-3-carboxamide, 1,1-dioxides
US6174868B1 (en) 1992-09-10 2001-01-16 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
EP0773029A4 (en) 1993-07-19 1997-09-03 Tokyo Tanabe Co HEPATITIS C VIRUS PROLIFERATION INHIBITOR
US6005103A (en) 1993-11-19 1999-12-21 Warner-Lambert Company Pyrone derivatives as protease inhibitors and antiviral agents
HUT77668A (hu) 1993-11-19 1998-07-28 Parke, Davis & Company Vírusellenes hatású 5,6-dihidropiron-származékok és hatóanyagként azokat tartalmazó gyógyszerkészítmények
SK283240B6 (sk) 1993-11-19 2003-04-01 Parke, Davis & Company 5,6-Dihydropyrónové deriváty ako inhibítory proteázy a protivírusové činidlá a farmaceutická kompozícia obsahujúca tieto deriváty
US5504104A (en) 1993-11-19 1996-04-02 Warner-Lambert Company Tricyclic pyrone derivatives as protease inhibitors and antiviral agents
US5789440A (en) 1993-11-19 1998-08-04 Warner-Lambert Company 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
US5834506A (en) 1996-11-01 1998-11-10 Warner-Lambert Company Dihydropyrones with improved antiviral activity
NZ510013A (en) 1998-09-11 2003-11-28 Warner Lambert Co Dihydropyrones with selected heterocycles replacing the phenyls bearing polar substituents used as HIV protease inhibitors
US6512006B1 (en) 1999-12-09 2003-01-28 Warner-Lambert Company HIV protease inhibitors
EP1256628A3 (en) 2001-05-10 2003-03-19 Agouron Pharmaceuticals, Inc. Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof
DOP2003000641A (es) 2002-05-10 2003-11-15 Pfizer Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan
US7148226B2 (en) * 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
PL1781662T3 (pl) * 2004-08-18 2011-08-31 Pfizer Inhibitory zależnej od RNA polimerazy RNA wirusa zapalenia wątroby typu C, i kompozycje i terapie wykorzystujące je

Also Published As

Publication number Publication date
MA28803B1 (fr) 2007-08-01
CN101006092B (zh) 2013-04-17
DK1781662T3 (da) 2011-06-27
GEP20094751B (en) 2009-08-10
ZA200700779B (en) 2008-11-26
CA2577525A1 (en) 2006-02-23
RS51794B (en) 2011-12-31
CN101006092A (zh) 2007-07-25
GT200500221A (es) 2006-06-21
EP1781662B1 (en) 2011-04-20
IL180933A0 (en) 2007-07-04
HRP20110458T1 (hr) 2011-07-31
CN101538268A (zh) 2009-09-23
MX2007001527A (es) 2007-03-27
PE20060677A1 (es) 2006-08-11
EP1781662A1 (en) 2007-05-09
US8268835B2 (en) 2012-09-18
CR8935A (es) 2007-07-24
TNSN07066A1 (fr) 2008-06-02
NL1029755C2 (nl) 2006-10-18
UY29068A1 (es) 2006-03-31
EA012605B1 (ru) 2009-10-30
DE602005027580D1 (de) 2011-06-01
ATE506364T1 (de) 2011-05-15
NZ552874A (en) 2010-04-30
PT1781662E (pt) 2011-07-01
AP2007003918A0 (en) 2007-02-28
KR100851178B1 (ko) 2008-08-08
CA2577525C (en) 2010-03-30
TWI376379B (en) 2012-11-11
US7622605B2 (en) 2009-11-24
CY1111480T1 (el) 2015-08-05
ECSP077264A (es) 2007-04-26
TW200612898A (en) 2006-05-01
UA88909C2 (ru) 2009-12-10
AR050699A1 (es) 2006-11-15
MY146123A (en) 2012-06-29
NL1029755A1 (nl) 2006-02-21
AP2313A (en) 2011-10-31
CR20110153A (es) 2011-04-26
IL192919A0 (en) 2009-02-11
CN101538268B (zh) 2011-07-27
BRPI0514425A (pt) 2008-06-10
NO20071274L (no) 2007-05-14
ES2361845T3 (es) 2011-06-22
AU2005273619A1 (en) 2006-02-23
US20090281122A1 (en) 2009-11-12
PL1781662T3 (pl) 2011-08-31
SI1781662T1 (sl) 2011-07-29
HN2005000449A (es) 2009-10-30
SV2007002202A (es) 2007-03-20
US20060122399A1 (en) 2006-06-08
JP2008509984A (ja) 2008-04-03
AU2005273619B2 (en) 2009-05-28
WO2006018725A1 (en) 2006-02-23
NI200700043A (es) 2008-01-02
US20070015764A1 (en) 2007-01-18
GEP20115305B (en) 2011-10-10
KR20070044057A (ko) 2007-04-26
EA200700338A1 (ru) 2007-08-31
JP4372195B2 (ja) 2009-11-25
IL180933A (en) 2011-08-31
US7151105B2 (en) 2006-12-19

Similar Documents

Publication Publication Date Title
HK1109617A1 (en) Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same c
AU2003224371A1 (en) Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
WO2007140200A3 (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
WO2007140254A3 (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
WO2007092888A3 (en) Hcv ns5b inhibitors
AP2406A (en) Macrocydic inhibitors of hepatitis C virus.
NL1025544A1 (nl) Remmers van rna-afhankelijk rna-polymerase van hepatitis-c-virus en preparaten en behandelingen waarbij ze worden gebruikt.
WO2004073599A3 (en) Inhibitors of hepatitis c virus, compositions and treatments using the same
IL198248A0 (en) Hepatitis c virus inhibitors and compositions comprising the same
AU2003256619A8 (en) Thionucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
HUP0402065A3 (en) Hepatitis c virus polymerase inhibitors with heterobicyclic structure, process for their preparation and pharmaceutical compositions containing them
HUP0400726A3 (en) Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
WO2004003138A3 (en) Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
TW200745035A (en) Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
WO2007092645A3 (en) Novel hcv inhibitor combinations and methods
IL182583A0 (en) 4-methoxymethyl-pyrrolidine-2-carboxylic acid compounds and derivatives thereof as hepatitis c virus inhibitors
IL177503A0 (en) Inhibitors of hepatitis c virus ns3 protease
EP1758453A4 (en) NUCLEOSIDE ANALOGUES OF C-PURINE AS RNA-DEPENDENT VIRAL RNA-POLYMERASE INHIBITORS
EP1766094A4 (en) INFLUENZA VIRUS VACCINE COMPOSITION AND METHODS OF USE
SI2209789T1 (sl) Ciklopropil zliti indolobenzazepin hcv ns5b inhibitorji
EP1771442A4 (en) INHIBITORS OF VIRAL POLYMERASE
WO2009029384A3 (en) Compounds for the treatment of hepatitis c
WO2005034850A3 (en) Cycloalkyl heterocycles for treating hepatitis c virus
HK1109069A1 (en) Vaccine composition against hepatitis c virus
EP1450809A4 (en) NUCLEOSIDES, THEIR PREPARATION AND USE AS AN INHIBITORS OF RNA VIRUS POLYMERASES

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230805